Living with Dravet Syndrome
Who We Are
A Better Tomorrow for People Living with Rare Genetic Epilepsies
Epygenix is a clinical stage biopharmaceutical company focused on developing treatments for rare and intractable genetic epilepsies. Powered by a first-of-its-kind, highly predictive, genetic screening platform that validates treatment responsiveness, our multi-asset pipeline of preclinically validated drug candidates targets Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS), and other forms of genetic epilepsies. While there are multiple anti-seizure medications available, to date none provide the complete efficacy, safety, and ease of administration sought by the epilepsy community. There remains a high unmet need for treatment alternatives and we are passionate about changing the way epileptic drugs are discovered and developed.
Today the Epygenix team has accomplished preclinical development, IND-enabling studies, and attained Orphan Drug and Rare Pediatric Disease Designations with the EPX portfolio of drug candidates.
After two decades of rigorous research, zebrafish have become a promising model for studying neurological disorders, especially rare genetic epilepsies. We believe these little fish have big potential.